<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: investment", fill: "#ffdead"},
{source: "1: investment", target: "1: common stock", fill: "#ffdead"},
{source: "1: common stock", target: "1: speculative", fill: "#ffdead"},
{source: "1: investment", target: "8: development", fill: "#dda0dd"},
{source: "8: development", target: "8: stage company", fill: "#dda0dd"},
{source: "8: stage company", target: "8: inception one", fill: "#dda0dd"},
{source: "8: inception one", target: "8: been private", fill: "#dda0dd"},
{source: "8: development", target: "15: demonstrate clinically", fill: "#fd0e35"},
{source: "15: demonstrate clinically", target: "15: regulatory", fill: "#fd0e35"},
{source: "15: regulatory", target: "15: authorities", fill: "#fd0e35"},
{source: "15: authorities", target: "15: financial resources relative", fill: "#fd0e35"},
{source: "15: financial resources relative", target: "15: competitors", fill: "#fd0e35"},
{source: "15: competitors", target: "15: appropriate marketing partner", fill: "#fd0e35"},
{source: "15: appropriate marketing partner", target: "15: availability", fill: "#fd0e35"},
{source: "15: availability", target: "15: reimbursement", fill: "#fd0e35"},
{source: "15: reimbursement", target: "15: products by", fill: "#fd0e35"},
{source: "15: products by", target: "15: third party payors", fill: "#fd0e35"},
{source: "15: third party payors", target: "15: Incidents ", fill: "#fd0e35"},
{source: "15: Incidents ", target: "15: manufacturing", fill: "#fd0e35"},
{source: "15: manufacturing", target: "15: distribution disruptions", fill: "#fd0e35"},
{source: "15: demonstrate clinically", target: "21: additional", fill: "#00755e"},
{source: "21: additional", target: "21: operations", fill: "#00755e"},
{source: "21: operations", target: "21: available on", fill: "#00755e"},
{source: "21: available on", target: "21: available at", fill: "#00755e"},
{source: "21: additional", target: "START_HERE", fill: "#00755e"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
    <tr>
      <td>Commercial and Professional Services</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Comment</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Covert monitoring</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock_dividend">Common stock dividend</a></td>
      <td>A common stock dividend is the dividend paid to common stock owners from the profits of the company.  Like other dividends, the payout is in the form of either cash or stock.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preferred_stock">Preferred stock</a></td>
      <td>Preferred stock (also called preferred shares, preference shares, or simply preferreds) is a component of share capital that may have any combination of features not possessed by common stock, including properties of both an equity and a debt instrument, and is generally considered a hybrid instrument. Preferred stocks are senior (i.e., higher ranking) to common stock but subordinate to bonds in terms of claim (or rights to their share of the assets of the company, given that such assets are payable to the returnee stock bond) and may have priority over common stock (ordinary shares) in the payment of dividends and upon liquidation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Matthiola_incana">Matthiola incana</a></td>
      <td>Matthiola incana is a species of flowering plant in the cabbage family Brassicaceae. Common names include Brompton stock, common stock, hoary stock, ten-week stock, and gilly-flower.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Consolidation_(business)">Consolidation (business)</a></td>
      <td>In business, consolidation or amalgamation is the merger and acquisition of many smaller companies into a few much larger ones. In the context of financial accounting, consolidation refers to the aggregation of financial statements of a group company as consolidated financial statements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stock_market">Stock market</a></td>
      <td>A stock market, equity market, or share market is the aggregation of buyers and sellers of stocks (also called shares), which represent ownership claims on businesses; these may include securities listed on a public stock exchange, as well as stock that is only traded privately, such as shares of private companies which are sold to investors through equity crowdfunding platforms. Investment is usually made with an investment strategy in mind.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Class_B_share">Class B share</a></td>
      <td>In finance, a Class B share or Class C share is a designation for a share class of a common or preferred stock that typically has strengthened voting rights or other benefits compared to a Class A share that may have been created. The equity structure, or how many types of shares are offered, is determined by the corporate charter.B share can also refer to various terms relating to stock classes:\n\nB share (mainland China), a class of stock on the Shanghai and Shenzhen stock exchanges\nB share (NYSE), a class of stock on the New York Stock ExchangeMost of the time, Class B shares may have lower repayment priorities in the event a company declares bankruptcy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Personal_development">Personal development</a></td>
      <td>Personal development or self improvement consists of activities that develop a person's capabilities and potential, build human capital, facilitate employability, and enhance quality of life and the realization of dreams and aspirations. Personal development may take place over the course of an individual's entire lifespan and is not limited to one stage of a person's life.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Reimbursement">Reimbursement</a></td>
      <td>Reimbursement is the act of compensating someone for an out-of-pocket expense by giving them an amount of money equal to what was spent.Companies, governments and nonprofit organizations may compensate their employees or officers for necessary and reasonable expenses; under US\nlaw, these expenses may be deducted from taxes by the organization and treated as untaxed income for the recipient provided that accountability conditions are met. UK law provides for deductions for travel and subsistence.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Business_mileage_reimbursement_rate">Business mileage reimbursement rate</a></td>
      <td>The business mileage reimbursement rate is an optional standard mileage rate used in the United States for purposes of computing the allowable business deduction, for Federal income tax purposes under the Internal Revenue Code, at 26 U.S.C. § 162, for the business use of a vehicle. Under the law, the taxpayer for each year is generally entitled to deduct either the actual expense amount, or an amount computed using the standard mileage rate, whichever is greater.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ERISA_reimbursement">ERISA reimbursement</a></td>
      <td>In the United States, ERISA reimbursement refers to the efforts of an ERISA Plan administrator (an insurer) to obtain repayment from an insured person who had previously received payments for personal injury medical bills.When an insurer pays a injury claim to someone, the insurer can seize cash settlements from whoever caused the injury. This “right of reimbursement” is essentially a subrogation claim.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Health_reimbursement_account">Health reimbursement account</a></td>
      <td>A Health Reimbursement Account, formally a Health Reimbursement Arrangement (HRA), is a type of US employer-funded health benefit plan that reimburses employees for out-of-pocket medical expenses and, in limited cases, to pay for health insurance plan premiums.An HRA is not truly an account, since it does not place funds under a separate legal title. Instead, it is an agreement under which the employee can submit qualified health expenses to the employer for reimbursement.Following implementation of the Affordable Care Act, HRAs must be integrated with a qualified employer-sponsored group health insurance plan to avoid excise tax penalties.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Capitation_(healthcare)">Capitation (healthcare)</a></td>
      <td>Capitation is a payment arrangement for health care service providers. It pays a set amount for each enrolled person assigned to them, per period of time, whether or not that person seeks care.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Fee_Reimbursement_Scheme_(Andhra_Pradesh)">Fee Reimbursement Scheme (Andhra Pradesh)</a></td>
      <td>The Fee Reimbursement Scheme (also known as the Post-matric Scholarship Scheme) is a student education sponsorship programme of the Government of Andhra Pradesh. It supports students from lower economic strata in the state.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Additional_Mathematics">Additional Mathematics</a></td>
      <td>Additional Mathematics is a qualification in mathematics, commonly taken by students in high-school (or GCSE exam takers in the United Kingdom). It is applied to a range of problems set out in a different format and wider content to the standard Mathematics at the same level.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Additional_member_system">Additional member system</a></td>
      <td>The additional member system (AMS) is a mixed electoral system under which most representatives are elected in single-member districts (SMDs), and the other "additional members" are elected to make the seat distribution in the chamber more proportional to the way votes are cast for party lists. It is distinct from parallel voting (also known as the supplementary member system) in that the "additional member" seats are awarded to parties taking into account seats won in SMDs (referred to as compensation or "top-up"), which is not done under parallel voting (a non-compensatory method).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Superintendent_of_police_(India)">Superintendent of police (India)</a></td>
      <td>Superintendent of police or SP is a senior rank in Indian Police Service or IPS. Superintendent of Police in Hindi means पुलिस अधीक्षक. They have one Star and one Ashoka emblem on their shoulders and below IPS is written.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Latin_Extended_Additional">Latin Extended Additional</a></td>
      <td>Latin Extended Additional is a Unicode block.\nThe characters in this block are mostly precomposed combinations of Latin letters with one or more general diacritical marks.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Order_of_Australia">Order of Australia</a></td>
      <td>The Order of Australia is an honour that recognises Australian citizens and other persons for outstanding achievement and service. It was established on 14 February 1975 by Elizabeth II, Queen of Australia, on the advice of the Australian Government.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Additionality">Additionality</a></td>
      <td>Additionality is the property of an activity being additional by adding something new to the context. It is a determination of whether an intervention has an effect when  compared to a baseline.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Additional_secretary_to_the_Government_of_India">Additional secretary to the Government of India</a></td>
      <td>Additional Secretary (often abbreviated as AS, GoI or Union Additional Secretary or Additional Secretary to Government of India) is a post and a rank under the Central Staffing Scheme of the Government of India. The authority for creation of this post solely rests with Cabinet of India.Additional secretary is mostly a career civil servant, generally from the Indian Administrative Service, and is a government official of high seniority.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Additional_insured">Additional insured</a></td>
      <td>In insurance policies, an additional insured is a person or organization who enjoys the benefits of being insured under an insurance policy, in addition to whoever originally purchased the insurance policy. The term generally applies within liability insurance and property insurance, but is an element of other policies as well.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>ALFACELL CORP             Item 1A     Risk Factors                                                                     18    Item 1A RISK FACTORS             An  <font color="blue">investment</font> in our <font color="blue">common stock</font> is  <font color="blue">speculative</font>  and involves a high  degree of risk</td>
    </tr>
    <tr>
      <td>You  should  <font color="blue">carefully</font>  consider  the  risks and  <font color="blue">uncertainties</font>  described  below and the other  information  in this Form 10-K and our other SEC  filings before  deciding  whether to <font color="blue">purchase shares</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>If any  of the <font color="blue">following risks actually</font> occur, our business and operating  results could  be harmed</td>
    </tr>
    <tr>
      <td>This could cause the trading  price of our common  stock to decline,  and you may lose all or part of your <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>We have  incurred  losses  since  inception  and  anticipate  that we will incur  <font color="blue">continued losses</font> for the foreseeable  future</td>
    </tr>
    <tr>
      <td>We do not have a <font color="blue">current source</font> of  <font color="blue">product revenue</font> and may never be profitable</td>
    </tr>
    <tr>
      <td>We are a  <font color="blue">development</font>  <font color="blue">stage company</font> and since our <font color="blue">inception one</font> of the  principal  sources of our working  capital has <font color="blue">been private</font>  sales of our common  stock</td>
    </tr>
    <tr>
      <td>We  incurred  net losses of  <font color="blue">approximately</font>  dlra7cmam810cmam000,  dlra6cmam462cmam000  and  dlra5cmam070cmam000   for  the  fiscal  years  ended  July  31,  2006,   2005  and  2004,  <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>We may  never achieve <font color="blue">revenue sufficient</font> for us to <font color="blue">attain <font color="blue">profitability</font></font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">profitability</font>  will  depend  on our  ability  to  develop,  obtain  <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font> for, and <font color="blue"><font color="blue">effective</font>ly market</font> ONCONASE(R) <font color="blue">as well as entering</font>  <font color="blue">into strategic</font>  alliances for the  <font color="blue">development</font> of new drug  <font color="blue">candidates</font>  from the  out-licensing of our <font color="blue">proprietary</font> RNase <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">commercialization</font> of our  <font color="blue">pharmaceutical</font>  products  involves  a  number  of  <font color="blue">significant</font>  <font color="blue">challenges</font></td>
    </tr>
    <tr>
      <td>In  particular our ability to  <font color="blue">commercialize</font>  ONCONASE(R)  <font color="blue">depends on</font> the success of  our clinical <font color="blue">development</font> programs, our efforts to obtain <font color="blue"><font color="blue">regulatory</font> approval</font> and  our sales and  marketing  efforts or those of our  marketing  partners,  if any,  <font color="blue">directed at physicians</font>,  patients and  third-party  payors</td>
    </tr>
    <tr>
      <td>A number of factors  could affect these efforts including:          o     Our ability to <font color="blue"><font color="blue">demonstrate</font> clinically</font> that our products have utility              and are safe;        o     Delays or refusals by <font color="blue">regulatory</font>  <font color="blue">authorities</font> in granting  marketing              approvals;        o     Our limited <font color="blue">financial resources relative</font> to our <font color="blue">competitors</font>;        o     Our ability to obtain an <font color="blue"><font color="blue">appropriate</font> marketing partner</font>;        o     The  <font color="blue">availability</font>  and level of  <font color="blue">reimbursement</font>  for our  <font color="blue">products by</font>              <font color="blue"><font color="blue">third party</font> payors</font>;        o     <font color="blue">Incidents </font>of adverse reactions to our products;        o     Misuse of our products and unfavorable  publicity that could result;              and        o     The occurrence of <font color="blue">manufacturing</font> or <font color="blue"><font color="blue">distribution</font> disruptions</font></td>
    </tr>
    <tr>
      <td>18  <PAGE>          We  will  seek  to  generate  revenue  through  licensing,  marketing  and  <font color="blue">development</font>  <font color="blue">arrangements</font>  prior  to  receiving  revenue  from  the  sale of our  products</td>
    </tr>
    <tr>
      <td>To  date  we  have  not   consummated  any  licensing  or  marketing  <font color="blue">arrangements</font>  and we  may  not be  able  to  <font color="blue">successfully</font>  consummate  any  such  <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">entered into</font> several <font color="blue">development</font> <font color="blue">arrangements</font>,  which have  resulted  in limited  revenues  for us</td>
    </tr>
    <tr>
      <td>However,  we cannot  ensure  that these  <font color="blue">arrangements</font> or future <font color="blue">arrangements</font>,  if any, will result in <font color="blue">significant</font> amounts  of revenue for us</td>
    </tr>
    <tr>
      <td>We, therefore, are unable to predict the extent of any future  losses or the time required to achieve <font color="blue">profitability</font>, if at all</td>
    </tr>
    <tr>
      <td>We may need  <font color="blue">additional</font>  financing  to  continue  <font color="blue">operations</font>,  which  may not be  <font color="blue">available on</font> acceptable terms, if it is <font color="blue">available at</font> all</td>
    </tr>
    <tr>
      <td>We  may  need  <font color="blue">additional</font>  financing  in  order  to  continue  <font color="blue">operations</font>,  including  <font color="blue">completion</font>  of our  current  clinical  trials  and  filing  marketing  <font color="blue"><font color="blue">registration</font>s</font>  for ONCONASE(R) with the FDA in the United States,  with the EMEA  in  Europe  and with  the TGA in  Australia</td>
    </tr>
    <tr>
      <td>If the  results  from our  current  <font color="blue">clinical trial</font> do not  <font color="blue">demonstrate</font>  the efficacy and safety of  ONCONASE(R)  for  malignant  <font color="blue">mesothelioma</font>,  our  ability  to  raise  <font color="blue">additional</font>  capital  will  be  <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>Even if <font color="blue">regulatory</font> <font color="blue">applications</font> for <font color="blue">marketing approvals</font> are  filed and approved,  we may need <font color="blue">additional</font>  financing to continue <font color="blue">operations</font> if  we are unable to generate  <font color="blue">sufficient cash flow</font> to support our <font color="blue">operations</font>  prior  to the time our <font color="blue">current <font color="blue">cash reserves</font></font> are depleted</td>
    </tr>
    <tr>
      <td>During the <font color="blue">fiscal year</font> ended  July 31,  2006,  we received  <font color="blue">approximately</font>  dlra12dtta3  million in <font color="blue">net proceeds as</font> a  result of private  <font color="blue">placements</font>  of <font color="blue">common stock</font> and  warrants,  and  exercises of  <font color="blue">stock options</font> and warrants</td>
    </tr>
    <tr>
      <td>We expect that <font color="blue">such net proceeds</font>  together with our  <font color="blue">cash reserves</font>,  will be sufficient to fund our <font color="blue">operations</font>  through July 31, 2008  <font color="blue">based on</font> our expected level of <font color="blue">expenditures</font></td>
    </tr>
    <tr>
      <td>However,  to assure our ability to  continue our  <font color="blue">operations</font>  beyond this date,  we <font color="blue">may continue</font> to seek  <font color="blue">additional</font>  financing  through equity or debt  <font color="blue">financings</font> but we cannot be sure that we will  be able to  raise  capital  on  favorable  terms or at all</td>
    </tr>
    <tr>
      <td>We may also  obtain  <font color="blue">additional</font>  capital  through the exercise of  outstanding  options and warrants,  although we cannot  provide any  assurance  of such  exercises  or estimate  the  amount  of  capital  we  will  receive,  if any</td>
    </tr>
    <tr>
      <td>If we are  required  to  raise  <font color="blue">additional</font>  capital  to fund  further  <font color="blue">operations</font>  and are  unable to do so, our  <font color="blue">operations</font> will be severely  curtailed and our business and financial  condition  will be <font color="blue">materially</font> <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>We  cannot  predict  how long it will  take us nor how  much it will  cost us to  complete part two of our <font color="blue">Phase III </font>trial because it is a <font color="blue">survival study</font></td>
    </tr>
    <tr>
      <td>We currently  have ongoing a two-part  <font color="blue">Phase III </font>trial of ONCONASE(R) as a  treatment for malignant  <font color="blue">mesothelioma</font></td>
    </tr>
    <tr>
      <td>The first part of the <font color="blue">clinical trial</font> has  been  completed and the second  <font color="blue">confirmatory</font>  part is <font color="blue">still ongoing</font> for which we  have  exceeded the full  <font color="blue">enrollment</font>  target of 316  patients</td>
    </tr>
    <tr>
      <td>The <font color="blue">first interim</font>  analysis  results <font color="blue">based on</font> the 105 events (deaths)  showed a two-month  survival  advantage of ONCONASE(R) + doxorubicin (12 months) vs</td>
    </tr>
    <tr>
      <td>These results were  <font color="blue">consistent with</font> the results from the first part of the trial  and were the basis for our decision to continue the trial</td>
    </tr>
    <tr>
      <td>The <font color="blue">primary endpoint</font>  of the <font color="blue">Phase III </font> clinical  trial is  survival,  <font color="blue">which tracks</font> the length of time  patients  enrolled in the study live</td>
    </tr>
    <tr>
      <td><font color="blue">According </font>to the  protocol,  a sufficient  number of <font color="blue"><font color="blue">patient deaths</font> must</font> occur in order to perform the required statistical  analyses to determine the efficacy of ONCONASE(R) in patients with  unresectable  (inoperable)  malignant  <font color="blue">mesothelioma</font></td>
    </tr>
    <tr>
      <td>Since it is  impossible  to <font color="blue">predict with</font>  <font color="blue">certainty</font> when these <font color="blue">patient deaths</font> in the <font color="blue">Phase III </font>trial will occur, we do not  have the <font color="blue">capability</font> of <font color="blue">reasonably</font> determining when a sufficient number of deaths  will occur,  nor when we will be able to file for marketing  <font color="blue"><font color="blue">registration</font>s</font>  with  the FDA, EMEA and TGA          In  addition,  clinical  trials are very  costly and time  consuming</td>
    </tr>
    <tr>
      <td>The  length of time required to complete a <font color="blue">clinical trial</font> <font color="blue">depends on</font> several  factors  including the size of the <font color="blue">patient population</font>,  the ability of patients to get to  the site of the <font color="blue">clinical study</font>, and the criteria for determining  <font color="blue">which patients</font>  are eligible to join the study</td>
    </tr>
    <tr>
      <td>Although we believe we <font color="blue">could modify</font> some of our  <font color="blue">expenditures</font>  to reduce our <font color="blue">cash outlays</font> in relation to our clinical  trials and  other NDA  related  <font color="blue">expenditures</font>,  we cannot  quantify  the <font color="blue">amount by which such</font>  <font color="blue">expenditures</font>  might  be  modified</td>
    </tr>
    <tr>
      <td>Hence,  a delay  in the  commercial  sale of  ONCONASE(R)  <font color="blue">would increase</font> the time frame of our <font color="blue">cash expenditure</font>  outflows and  may require us to seek <font color="blue">additional</font>  financing</td>
    </tr>
    <tr>
      <td>Such <font color="blue">capital financing may</font> not be  <font color="blue">available on</font> favorable terms or at all</td>
    </tr>
    <tr>
      <td>19  <PAGE>    If we fail to obtain the <font color="blue">necessary</font> <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font>,  we will not be allowed  to <font color="blue">commercialize</font> our drugs and will not generate <font color="blue">product revenue</font></td>
    </tr>
    <tr>
      <td>The FDA and comparable  <font color="blue">regulatory</font>  agencies in foreign  countries  impose  substantial   pre-market   approval   <font color="blue">requirements</font>   on  the   <font color="blue">introduction</font>   of  <font color="blue">pharmaceutical</font>   products</td>
    </tr>
    <tr>
      <td>These  <font color="blue">requirements</font>  involve  lengthy  and  detailed  pre-clinical   and  clinical   testing  and  other  costly  and  time  consuming  procedures</td>
    </tr>
    <tr>
      <td><font color="blue">Satisfaction  </font>of these  <font color="blue">requirements</font>  typically takes several years  depending on the level of <font color="blue">complexity</font> and novelty of the product</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot apply</font>  for FDA, EMEA or TGA approval to market  ONCONASE(R)  until the clinical  trials  and all other  <font color="blue">registration</font>  <font color="blue">requirements</font> have been met</td>
    </tr>
    <tr>
      <td>Drugs in late stages of  clinical  <font color="blue">development</font>  may fail to show the desired safety and efficacy  results  despite having progressed through initial clinical testing</td>
    </tr>
    <tr>
      <td>While limited trials  with our product have produced certain favorable  results,  we cannot be certain  that we will <font color="blue">successfully</font> complete Phase I, Phase II or <font color="blue">Phase III </font>testing of any  <font color="blue">compound within</font> any specific time period, if at all</td>
    </tr>
    <tr>
      <td>Furthermore, the FDA or the  company may suspend <font color="blue">clinical trial</font>s at any time <font color="blue">on various grounds</font>,  including a  finding  that the  subjects or  patients  are being  exposed to an  unacceptable  health  risk</td>
    </tr>
    <tr>
      <td>In  addition,  we cannot  apply for FDA,  EMEA or TGA approval to  market  ONCONASE(R) until  pre-clinical and <font color="blue">clinical trial</font>s have been completed</td>
    </tr>
    <tr>
      <td><font color="blue">Several  </font><font color="blue">factors could prevent</font> the  successful  <font color="blue">completion</font> or cause  <font color="blue">significant</font>  delays of these trials  including an <font color="blue">inability</font> to enroll the required  number of  patients or failure to  <font color="blue">demonstrate</font>  that the product is safe and  <font color="blue">effective</font>  in  humans</td>
    </tr>
    <tr>
      <td>Also if <font color="blue">safety concerns</font>  develop,  the FDA, EMEA and TGA <font color="blue">could stop</font> our  trials before <font color="blue">completion</font></td>
    </tr>
    <tr>
      <td>All statutes and <font color="blue">regulations</font>  governing the conduct of <font color="blue">clinical trial</font>s are  subject to change by various  <font color="blue">regulatory</font>  agencies,  including  the FDA,  in the  future,  <font color="blue">which could affect</font> the cost and duration of our  clinical  trials</td>
    </tr>
    <tr>
      <td>Any  <font color="blue">unanticipated costs</font> or delays in our <font color="blue">clinical studies would delay</font> our ability to  generate <font color="blue">product revenue</font>s and to raise <font color="blue">additional</font>  capital and could cause us to  be unable to fund the <font color="blue">completion</font> of the studies</td>
    </tr>
    <tr>
      <td>We may not  market  or sell any  product  for  which we have not  obtained  <font color="blue">regulatory</font>  approval</td>
    </tr>
    <tr>
      <td>We  cannot  assure  you that the FDA or other  <font color="blue">regulatory</font>  <font color="blue">agencies will ever approve</font> the use of our products  that are under  <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Further,  even after  approval,  <font color="blue">discovery</font> of <font color="blue">previously</font>  unknown  <font color="blue">problems could</font> result in <font color="blue">additional</font>  <font color="blue">restrictions</font>, including withdrawal of our <font color="blue">products from</font> the market</td>
    </tr>
    <tr>
      <td>If we fail to obtain the <font color="blue">necessary</font> <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font>,  we <font color="blue">cannot market</font>  or sell  our  products  in the  United  States,  or in other  countries  and our  long-term  viability  would  be  threatened</td>
    </tr>
    <tr>
      <td>If we fail to  achieve  <font color="blue">regulatory</font>  approval or foreign marketing  <font color="blue">authorizations</font> for ONCONASE(R) we will not have a  <font color="blue">saleable product</font> or <font color="blue">product revenue</font>s for quite some time, if at all, and may not  be able to continue <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We are and will be <font color="blue"><font color="blue">dependent</font> upon third parties</font> for  <font color="blue">manufacturing</font> our products</td>
    </tr>
    <tr>
      <td>If these  third  parties  do not devote  sufficient  time and  resources  to our  products our revenues and <font color="blue">profits may</font> be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>We do not have the required  <font color="blue">manufacturing</font>  <font color="blue">facilities</font> to <font color="blue">manufacture</font>  our  product</td>
    </tr>
    <tr>
      <td>We  presently  rely  on  third  parties  to  perform  certain  of  the  <font color="blue">manufacturing</font>  processes for the production of  ONCONASE(R)  for use in clinical  trials</td>
    </tr>
    <tr>
      <td>Currently, we <font color="blue">contract with</font> Scientific Protein Laboratories, LLC for the  <font color="blue">manufacturing</font>  of ranpirnase  (<font color="blue">protein drug</font> substance) from the oocytes,  or the  <font color="blue">unfertilized</font>  eggs,  of the Rana pipiens  frog,  which is found in the Northwest  United  States and is commonly  called the leopard  frog</td>
    </tr>
    <tr>
      <td>We contract  with Ben  Venue  Corporation for the <font color="blue">manufacturing</font> of ONCONASE(R) and with Cardinal Health  and Apptuit for the labeling,  storage and shipping of ONCONASE(R)  for clinical  trial use</td>
    </tr>
    <tr>
      <td>We utilize the services of these <font color="blue">third party</font> <font color="blue">manufacture</font>rs  solely on  an as needed <font color="blue">basis with terms</font> and <font color="blue">prices customary</font> for our industry</td>
    </tr>
    <tr>
      <td>We use FDA GMP licensed  <font color="blue">manufacture</font>rs for ranpirnase and ONCONASE(R)</td>
    </tr>
    <tr>
      <td>We  have identified  several  <font color="blue">alternative</font>  service  providers for the  <font color="blue">manufacturing</font>  services  for which we may  contract</td>
    </tr>
    <tr>
      <td>In order to replace an  existing  service  provider  we must  amend  our  IND to  notify  the FDA of the new  <font color="blue">manufacture</font>r</td>
    </tr>
    <tr>
      <td>Although  the FDA  <font color="blue">generally</font>  will not  suspend or delay a  clinical  trial as a  result of  replacing  an existing  <font color="blue">manufacture</font>r,  the FDA has the  authority  to  suspend or delay a <font color="blue">clinical trial</font> if, among other grounds, human subjects are or  would be exposed to an unreasonable and <font color="blue">significant</font> risk of illness or injury as  a result of the <font color="blue">replacement</font> <font color="blue">manufacture</font>r</td>
    </tr>
    <tr>
      <td>20  <PAGE>          We intend to <font color="blue">rely on third parties</font> to <font color="blue">manufacture</font> our products if they are  approved for sale by the <font color="blue">appropriate</font> <font color="blue">regulatory</font> agencies and are <font color="blue">commercialize</font>d</td>
    </tr>
    <tr>
      <td>Third party  <font color="blue">manufacture</font>rs may not be able to meet our needs <font color="blue">with respect</font> to the  timing,  quantity or quality of our products or to <font color="blue">supply products on</font> acceptable  terms</td>
    </tr>
    <tr>
      <td>Because we do not have marketing, sales or <font color="blue"><font color="blue">distribution</font> <font color="blue">capabilities</font></font>,  we expect  to contract  with third  parties for these  functions  and we will  therefore be  <font color="blue"><font color="blue">dependent</font> upon such third parties</font> to market, sell and distribute our products in  order for us to <font color="blue">generate revenues</font></td>
    </tr>
    <tr>
      <td>We currently have no sales,  marketing or  <font color="blue">distribution</font>  <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>In  order to <font color="blue">commercialize</font> any product <font color="blue">candidates</font> for which we receive FDA or non US  approval,  we expect to <font color="blue">rely on established</font>  <font color="blue">third party</font>  strategic  partners to  perform  these  functions</td>
    </tr>
    <tr>
      <td>To date,  we have not <font color="blue">entered into</font> any  marketing or  licensing  <font color="blue">agreements</font> for  ONCONASE(R)</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you we will be able to  establish or maintain  <font color="blue">relationships with one</font> or more bio<font color="blue">pharmaceutical</font> or other  marketing companies with existing  <font color="blue">distribution</font>  systems and <font color="blue">direct sales forces</font>  to market any or all of our product <font color="blue">candidates</font>, on acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>In  addition,  we  expect  to  begin  to  incur  <font color="blue">significant</font>  expenses  in  determining  our  <font color="blue">commercialization</font>  strategy <font color="blue">with respect</font> to one or more of our  product  <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">determination</font> of our  <font color="blue">commercialization</font>  <font color="blue">strategy with</font>  respect to a product candidate will depend on a number of factors, including:          o     the  extent to which we are  successful  in  securing  <font color="blue">collaborative</font>              partners  to  offset  some or all of the  funding  <font color="blue">obligations</font>  with              respect to product <font color="blue">candidates</font>;        o     the extent to which our <font color="blue">agreement with</font> our <font color="blue">collaborators</font>  <font color="blue">permits us</font>              to  exercise  marketing  or  promotion  rights  with  respect to the              product candidate;        o     how our product  <font color="blue">candidates</font>  compare to  <font color="blue">competitive</font>  products  with              respect to  labeling,  pricing,  <font color="blue">therapeutic</font>  effect,  and method of              delivery; and        o     whether  we are  able  to  establish  <font color="blue">agreements</font>  with  third  party              <font color="blue">collaborators</font>,  including large bio<font color="blue">pharmaceutical</font> or other marketing              companies,  <font color="blue">with respect</font> to any of our product  <font color="blue">candidates</font>  on terms              that are acceptable          A number of these factors are outside of our control and will be <font color="blue">difficult</font>  to determine</td>
    </tr>
    <tr>
      <td>Our product <font color="blue">candidates</font> may not be <font color="blue">accepted by</font> the market</td>
    </tr>
    <tr>
      <td>Even if <font color="blue">approved by</font> the FDA and other <font color="blue">regulatory</font> <font color="blue">authorities</font>,  our product  <font color="blue">candidates</font> may not achieve market  <font color="blue">acceptance</font>,  which means we would not receive  <font color="blue">significant</font>  revenues  from  these  products</td>
    </tr>
    <tr>
      <td><font color="blue">Approval  </font>by  the  FDA  does  not  <font color="blue">necessarily</font>  mean that the medical  <font color="blue">community</font>  will be convinced of the relative  safety,  efficacy  and  cost-<font color="blue">effective</font>ness  of our products as compared to other  products</td>
    </tr>
    <tr>
      <td>In addition,  <font color="blue">third party</font> reimbursers such as insurance companies and  HMOs may be reluctant to <font color="blue">reimburse expenses</font> relating to our products</td>
    </tr>
    <tr>
      <td>We <font color="blue">depend upon</font> Kuslima Shogen and our other key personnel and may not be able to  retain these employees or recruit qualified <font color="blue">replacement</font> or <font color="blue">additional</font> personnel,  which would have a material adverse affect on our business</td>
    </tr>
    <tr>
      <td>We are highly  <font color="blue">dependent</font>  upon our founder,  Chairman and Chief  Executive  Officer, Kuslima Shogen</td>
    </tr>
    <tr>
      <td>Kuslima Shogenapstas talents, efforts, personality,  vision  and  <font color="blue">leadership</font>  have been,  and continue to be,  critical to our  success</td>
    </tr>
    <tr>
      <td>The  <font color="blue">diminution</font> or loss of the services of Kuslima Shogen, and any <font color="blue">negative market</font> or  industry  <font color="blue">perception</font> arising from that <font color="blue">diminution</font> or loss, would have a material  adverse effect on our business</td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>of  the  specialized  scientific  nature  of  our  business,  our  continued  success  also is  <font color="blue">dependent</font>  upon our  ability to attract  and retain  qualified <font color="blue">management</font> and <font color="blue">scientific personnel</font></td>
    </tr>
    <tr>
      <td>There is intense <font color="blue">competition</font> for  qualified  personnel  in the  <font color="blue">pharmaceutical</font>  field</td>
    </tr>
    <tr>
      <td>As our  company  grows our  <font color="blue">inability</font>  to  attract  qualified  <font color="blue">management</font>  and  scientific  personnel  could  <font color="blue">materially</font>  <font color="blue">adversely</font>  affect  our  research  and  <font color="blue">development</font>   programs,   the  <font color="blue">commercialization</font> of our products and the <font color="blue">potential revenue from product sales</font></td>
    </tr>
    <tr>
      <td>21  <PAGE>          We do not have  <font color="blue">employment</font>  contracts  with  Kuslima  Shogen or any of our  other <font color="blue">management</font> and <font color="blue">scientific personnel</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">proprietary</font> <font color="blue">technology</font> and <font color="blue"><font color="blue">patents may</font> offer only</font> limited <font color="blue">protection against</font>  <font color="blue">infringement</font> and the <font color="blue">development</font> by our <font color="blue">competitors</font> of <font color="blue">competitive</font> products</td>
    </tr>
    <tr>
      <td>We own two  patents  jointly  with the  United  States  <font color="blue">government</font></td>
    </tr>
    <tr>
      <td>We also own ten <font color="blue">United States  </font>patents with  expiration  dates ranging from 2006 to 2019,  four <font color="blue">European  </font>patents with  expiration  dates  ranging  from 2009 to 2016 and three  <font color="blue">Japanese  </font>patents  with  expiration  dates  ranging from 2010 to 2016</td>
    </tr>
    <tr>
      <td>We also own patent  <font color="blue">applications</font>  that are pending in  the United States,  Europe,  Japan,  and other foreign  countries</td>
    </tr>
    <tr>
      <td>The scope of  <font color="blue">protection afforded by patents</font> for <font color="blue">bio<font color="blue">technological</font> inventions</font> is uncertain, and  such un<font color="blue">certainty</font> applies to our <font color="blue">patents as well</font></td>
    </tr>
    <tr>
      <td>Therefore,  our <font color="blue">patents may</font> not  give us <font color="blue">competitive</font>  <font color="blue">advantages</font> or <font color="blue">afford us adequate</font>  <font color="blue">protection from competing</font>  products</td>
    </tr>
    <tr>
      <td>Furthermore,  others  may  in<font color="blue">dependent</font>ly  develop  products  that are  similar to our products, and <font color="blue">may design around</font> the claims of our patents</td>
    </tr>
    <tr>
      <td>Patent  <font color="blue">litigation</font> and <font color="blue">intellectual</font>  property <font color="blue">litigation</font> are expensive and our resources  are limited</td>
    </tr>
    <tr>
      <td>If we were to <font color="blue">become involved</font> in <font color="blue">litigation</font>,  we might not have the  funds or other <font color="blue">resources <font color="blue">necessary</font></font> to conduct the <font color="blue">litigation</font>  <font color="blue">effective</font>ly</td>
    </tr>
    <tr>
      <td>This  <font color="blue">might prevent us from protecting</font> our patents,  <font color="blue">from defending</font>  against claims of  <font color="blue">infringement</font>,  or both</td>
    </tr>
    <tr>
      <td>To date, we have not received any threats of <font color="blue">litigation</font>  regarding <font color="blue">patent issues</font></td>
    </tr>
    <tr>
      <td><font color="blue">Developments </font>by <font color="blue">competitors</font> may render our <font color="blue">products obsolete</font> or non-<font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td><font color="blue">In February  </font>2004,  the Food and Drug  Administration  granted <font color="blue">Eli Lilly </font>&amp;  Company  approval to sell its  Alimta(R)  <font color="blue">medication</font>  as an <font color="blue">orphan drug</font> to treat  patients with pleural <font color="blue">mesothelioma</font></td>
    </tr>
    <tr>
      <td>Alimta is a multi-targeted  antifolate that  is  based  upon  a  <font color="blue">different</font>  mechanism  of  action  than  ONCONASE(R)</td>
    </tr>
    <tr>
      <td>To our  knowledge,  no other company is developing a <font color="blue">product with</font> the same  mechanism of  <font color="blue">action as</font>  ONCONASE(R)</td>
    </tr>
    <tr>
      <td>However,  there may be other  companies,  <font color="blue">universities</font>,  research  teams or  <font color="blue">scientists</font>  who are  developing  products  to treat the same  <font color="blue">medical conditions</font> our products are intended to treat</td>
    </tr>
    <tr>
      <td><font color="blue">Eli Lilly </font>is, and some of  these other  companies,  <font color="blue">universities</font>,  research  teams or  <font color="blue">scientists</font>  are more  experienced and have greater clinical, marketing and <font color="blue">regulatory</font> <font color="blue">capabilities</font> and  managerial  and financial  <font color="blue">resources than</font> we do</td>
    </tr>
    <tr>
      <td>This <font color="blue">may enable them</font> to develop  products to treat the same <font color="blue">medical conditions</font> our products are intended to treat  before we are able to complete the <font color="blue">development</font> of our <font color="blue">competing product</font></td>
    </tr>
    <tr>
      <td>Our  business  is very  <font color="blue">competitive</font>  and  involves  rapid  changes  in the  <font color="blue">technologies</font>  involved  in  developing  new drugs</td>
    </tr>
    <tr>
      <td>If others  experience  rapid  <font color="blue">technological</font>  <font color="blue">development</font>,  our products may become obsolete before we are able  to <font color="blue">recover expenses</font>  incurred in developing our products</td>
    </tr>
    <tr>
      <td>We <font color="blue">will probably face</font>  new <font color="blue">competitors</font> as new <font color="blue">technologies</font>  develop</td>
    </tr>
    <tr>
      <td>Our success <font color="blue">depends on</font> our ability  to remain  <font color="blue">competitive</font> in the  <font color="blue">development</font> of new drugs or we may not be able to  compete <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td>We may be sued for <font color="blue">product <font color="blue">liability</font></font></td>
    </tr>
    <tr>
      <td>Our business  <font color="blue">exposes us</font> to potential  product  <font color="blue">liability</font>  that may have a  negative  effect on our financial  performance and our business  <font color="blue">generally</font></td>
    </tr>
    <tr>
      <td>The  <font color="blue">administration</font>  of drugs to humans,  whether in <font color="blue">clinical trial</font>s or <font color="blue">commercially</font>,  <font color="blue">exposes us</font> to  potential  product  and  <font color="blue">professional</font>  <font color="blue">liability</font>  risks which are  inherent in the testing, production, marketing and sale of new drugs for humans</td>
    </tr>
    <tr>
      <td><font color="blue">Product  </font><font color="blue">liability</font>  claims  can be  expensive  to defend and may result in large  judgments or <font color="blue">settlements</font>  against us, which could have a negative  effect on our  financial  performance and <font color="blue">materially</font> <font color="blue">adversely</font> affect our business</td>
    </tr>
    <tr>
      <td>We maintain  product  <font color="blue">liability</font>  insurance to protect our products and product  <font color="blue">candidates</font> in  <font color="blue">amounts customary</font> for companies in <font color="blue">businesses</font> that are similarly  situated,  but  our  insurance  coverage may not be  sufficient  to cover  claims</td>
    </tr>
    <tr>
      <td>Furthermore,  <font color="blue">liability</font> insurance coverage is becoming <font color="blue">increasingly</font> expensive and we cannot be  certain  that we will  always be able to  maintain  or  increase  our  insurance  <font color="blue">coverage at</font> an  affordable  price or in  sufficient  amounts to protect  against  <font color="blue">potential losses</font></td>
    </tr>
    <tr>
      <td>A product  <font color="blue">liability</font> claim,  <font color="blue">product recall</font> or other claim, as  well as any  claim for  uninsured  <font color="blue">liabilities</font>  or claim in  excess  of  insured  <font color="blue">liabilities</font>, may <font color="blue">significant</font>ly harm our business and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Even  if a product  <font color="blue">liability</font> claim is not successful,  <font color="blue">adverse publicity</font> and time and  expense of <font color="blue">defending such</font> a claim may <font color="blue">significant</font>ly interfere with our business</td>
    </tr>
    <tr>
      <td>22  <PAGE>    As of July 31, 2006,  we had a material  weakness in our  internal  <font color="blue">control over</font>  financial  reporting</td>
    </tr>
    <tr>
      <td>If we fail to  maintain an  <font color="blue">effective</font>  system of internal  control, we may not be able to <font color="blue">provide timely</font> and accurate <font color="blue">financial statements</font></td>
    </tr>
    <tr>
      <td>As more <font color="blue">fully described</font> in Item 9A, the Companyapstas  <font color="blue">management</font> assessed the  <font color="blue">effective</font>ness of the Companyapstas  internal <font color="blue">control over</font> financial  reporting as of  July 31, 2006</td>
    </tr>
    <tr>
      <td>In making this <font color="blue">assessment</font>,  it used the <font color="blue">criteria set forth by</font> the  <font color="blue">Committee  </font>of  Sponsoring  Organizations  of the Treadway  Commission  (COSO) in  Internal Control - Integrated Framework</td>
    </tr>
    <tr>
      <td>As a result of <font color="blue">management</font>apstas <font color="blue">assessment</font>,  <font color="blue">management</font> has concluded that, as of July 31, 2006, the Company did not maintain  <font color="blue">effective</font> internal <font color="blue">control over</font> financial reporting</td>
    </tr>
    <tr>
      <td>The  Public  Company  Accounting  Oversight  Board has  defined a material  weakness  as  a  <font color="blue">significant</font>   <font color="blue">deficiency</font>,   or   <font color="blue">combination</font>   of   <font color="blue">significant</font>  <font color="blue">deficiencies</font>,  that  results  in more than a remote  likelihood  that a material  <font color="blue">misstatement</font> of the annual or interim <font color="blue">financial statements</font> will not be prevented  or  detected</td>
    </tr>
    <tr>
      <td>Accordingly,  a  material  weakness  increases  the risk that the  financial information we report contains material errors</td>
    </tr>
    <tr>
      <td>Management,  <font color="blue">with oversight by</font> our Audit  Committee,  is in the process of  <font color="blue">implementing</font>  changes to the Companyapstas  internal  <font color="blue">control systems</font> and procedures  which are described in detail in Item 9A The steps we are taking to address the  material <font color="blue">weakness may</font> not be <font color="blue">effective</font>,  however</td>
    </tr>
    <tr>
      <td>If we are unable to implement  these changes  <font color="blue">effective</font>ly  or if other material  <font color="blue">weaknesses</font>  develop and we are  unable to <font color="blue">effective</font>ly  address these matters,  <font color="blue">there could</font> be a material adverse  effect on our business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we are unable to obtain favorable  <font color="blue">reimbursement</font> for our product  <font color="blue">candidates</font>,  their <font color="blue">commercial success may</font> be <font color="blue">severely hindered</font></td>
    </tr>
    <tr>
      <td>Our  ability to sell our future  products  may depend in large part on the  extent to which  <font color="blue">reimbursement</font>  for the costs of our products is available  from  <font color="blue">government</font>  entities,  <font color="blue">private health insurers</font>,  <font color="blue">managed care</font>  <font color="blue"><font color="blue">organization</font>s</font> and  others</td>
    </tr>
    <tr>
      <td>Third-party payors are <font color="blue">increasingly</font>  attempting to contain their costs</td>
    </tr>
    <tr>
      <td>We cannot  predict  actions  third-party  <font color="blue">payors may</font> take,  or whether they will  limit the  coverage  and level of  <font color="blue">reimbursement</font>  for our  products or refuse to  provide any <font color="blue">coverage at</font> all</td>
    </tr>
    <tr>
      <td>Reduced or partial  <font color="blue">reimbursement</font>  coverage  could  make our  products  less  attractive  to  patients,  suppliers  and  prescribing  physicians and may not be adequate for us to maintain price levels sufficient to  realize an  <font color="blue">appropriate</font>  return on our  <font color="blue">investment</font> in our product  <font color="blue">candidates</font> or  compete on price</td>
    </tr>
    <tr>
      <td>In some cases,  insurers and other healthcare payment <font color="blue"><font color="blue">organization</font>s</font> try to  encourage the use of <font color="blue">less expensive generic brands</font> and over-the-counter, or OTC,  products  through  their   <font color="blue">prescription</font>   benefits  coverage  and  <font color="blue">reimbursement</font>  policies</td>
    </tr>
    <tr>
      <td>These  <font color="blue"><font color="blue">organization</font>s</font> may make the generic <font color="blue">alternative</font> more attractive  to the patient by providing  <font color="blue">different</font>  amounts of <font color="blue">reimbursement</font> so that the net  cost of the  generic  product  to the  patient  is less  than  the net cost of a  <font color="blue">prescription</font>  brand product</td>
    </tr>
    <tr>
      <td><font color="blue">Aggressive </font><font color="blue">pricing policies by</font> our <font color="blue">generic product</font>  <font color="blue">competitors</font>  and the  <font color="blue">prescription</font>  benefits  policies of insurers  could have a  negative effect on our <font color="blue">product revenue</font>s and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Many <font color="blue">managed care</font>  <font color="blue"><font color="blue">organization</font>s</font>  negotiate the price of medical  services  and products and develop  <font color="blue">formularies</font>  for that purpose</td>
    </tr>
    <tr>
      <td><font color="blue">Exclusion </font>of a product  from a formulary  can lead to its  sharply  reduced  usage in the  managed  care  <font color="blue">organization</font>  patient  population</td>
    </tr>
    <tr>
      <td>If our products  are not included  within an  adequate  number  of  <font color="blue">formularies</font>  or  adequate  <font color="blue">reimbursement</font>  levels  are  not  provided, or if those policies  <font color="blue">increasingly</font> favor generic or OTC products,  our  market  share and  gross  margins  could be  <font color="blue">negatively</font>  affected,  as could our  overall business and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>The  <font color="blue">competition</font>  among  <font color="blue">pharmaceutical</font>  companies to have their  products  approved for  <font color="blue">reimbursement</font>  may also result in <font color="blue">downward pricing pressure</font> in the  industry  or in the  markets  where our  products  will  compete</td>
    </tr>
    <tr>
      <td>We may not be  successful in any efforts we take to mitigate the effect of a decline in average  <font color="blue">selling prices</font> for our products</td>
    </tr>
    <tr>
      <td>Any decline in our average <font color="blue">selling prices</font> would  also reduce our gross margins</td>
    </tr>
    <tr>
      <td>In  addition,  <font color="blue">managed care</font>  <font color="blue">initiatives</font>  to control  costs may  influence  primary  care  physicians  to refer  fewer  patients  to  <font color="blue">oncologists</font>  and other  <font color="blue">specialists</font></td>
    </tr>
    <tr>
      <td><font color="blue">Reductions </font>in these referrals could have a material adverse effect  on the size of our potential  market and increase costs to  <font color="blue">effective</font>ly  promote  our products</td>
    </tr>
    <tr>
      <td>23  <PAGE>          We are subject to <font color="blue">new legislation</font>,  <font color="blue">regulatory</font>  proposals and <font color="blue">managed care</font>  <font color="blue">initiatives</font>  that may increase our costs of compliance and <font color="blue">adversely</font>  affect our  ability to market our products, obtain <font color="blue">collaborators</font> and <font color="blue">raise capital</font></td>
    </tr>
    <tr>
      <td>There have been a number of <font color="blue">legislative</font> and <font color="blue">regulatory</font>  <font color="blue">proposals aimed at</font>  changing the healthcare system and <font color="blue">pharmaceutical</font> industry, including <font color="blue">reductions</font>  in the  cost of  <font color="blue">prescription</font>  products  and  changes  in the  levels  at  which  consumers   and   healthcare   providers   are   reimbursed   for  purchases  of  <font color="blue">pharmaceutical</font>  products</td>
    </tr>
    <tr>
      <td>For  example,  the  Prescription  Drug  and  <font color="blue">Medicare  </font>Improvement Act of 2003 provides <font color="blue">a Medicare </font><font color="blue">prescription</font> drug benefit that began  in 2006 and mandates other reforms</td>
    </tr>
    <tr>
      <td>Although we <font color="blue">cannot predict</font> the full effects  on our business of the  <font color="blue">implementation</font>  of this <font color="blue">new legislation</font>,  it is possible  that the new benefit, which will be managed by <font color="blue">private health insurers</font>, pharmacy  <font color="blue">benefit managers</font> and other <font color="blue">managed care</font> <font color="blue"><font color="blue">organization</font>s</font>,  will result in decreased  <font color="blue">reimbursement</font> for <font color="blue">prescription</font> drugs, which may further exacerbate industry-wide  pressure to reduce the <font color="blue">prices charged</font> for  <font color="blue">prescription</font>  drugs</td>
    </tr>
    <tr>
      <td>This <font color="blue">could harm</font>  our ability to market our products and generate  revenues</td>
    </tr>
    <tr>
      <td>As a  result  of  the  new  <font color="blue">Medicare  </font><font color="blue">prescription</font> drug benefit or any other proposals, we may determine to change our  <font color="blue">current manner</font> of operation,  provide <font color="blue">additional</font> benefits or change our contract  <font color="blue">arrangements</font>,  any of which  could  harm our  ability to  operate  our  business  <font color="blue">efficiently</font>, obtain <font color="blue">collaborators</font> and <font color="blue">raise capital</font></td>
    </tr>
    <tr>
      <td>Risks related to our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We were <font color="blue">relisted on</font> the Nasdaq  Capital Market after being delisted in 1999; our  stock is thinly  traded  and you may not be able to sell our stock when you want  to do so</td>
    </tr>
    <tr>
      <td><font color="blue">From April </font>1999,  when we were  <font color="blue">delisted from</font> Nasdaq,  until  <font color="blue">September </font>9,  2004,  when  we  were  relisted  on the  Nasdaq  Capital  Market,  there  was no  established  trading  market for our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>There is no  assurance  that we will be able to <font color="blue">comply with</font> all of the  listing  <font color="blue">requirements</font>  <font color="blue">necessary</font> to <font color="blue">remain listed on</font> the <font color="blue">Nasdaq Capital Market</font></td>
    </tr>
    <tr>
      <td>In addition,  our stock  remains  thinly  traded  and you may be unable to sell our common  stock  during  times when the <font color="blue">trading market</font> is limited</td>
    </tr>
    <tr>
      <td>The price of our <font color="blue">common stock</font> has been, and <font color="blue">may continue</font> to be, volatile</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our <font color="blue">common stock</font>,  like that of the securities of many  other  <font color="blue">development</font>  stage  bio<font color="blue">technology</font>  companies,  has fluctuated over a wide  range and it is likely that the price of our <font color="blue">common stock</font> will  fluctuate in the  future</td>
    </tr>
    <tr>
      <td>Over the past three  years,  the sale price for our  common  stock,  as  reported by <font color="blue">Nasdaq and the OTC Bulletin Board </font>has <font color="blue">fluctuated from</font> a low of dlra1dtta25  to a high of dlra10dtta07</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our <font color="blue">common stock</font> could be <font color="blue">impacted by</font> a  variety of factors, including:          o     <font color="blue">announcements</font>  of   <font color="blue">technological</font>   <font color="blue">innovations</font>  or  new  commercial              <font color="blue">products by</font> us or our <font color="blue">competitors</font>,        o     <font color="blue">disclosure</font>  of the  results of  pre-clinical  testing  and  clinical              <font color="blue">trials by us</font> or our <font color="blue">competitors</font>,        o     <font color="blue">disclosure</font> of the results of <font color="blue">regulatory</font> proceedings,        o     changes in <font color="blue">government</font> regulation,        o     <font color="blue">development</font>s  in the patents or other  <font color="blue">proprietary</font>  rights  owned or              <font color="blue">licensed by us</font> or our <font color="blue">competitors</font>,        o     public  concern as to the safety and efficacy of products  developed              by us or others,        o     <font color="blue">litigation</font>, and        o     <font color="blue">general market conditions</font> in our industry</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">stock market continues</font> to experience <font color="blue">extreme price</font> and  volume  <font color="blue">fluctuations</font></td>
    </tr>
    <tr>
      <td>These  <font color="blue">fluctuations</font>  have <font color="blue">especially</font>  affected the market  price  of many  bio<font color="blue">technology</font>  companies</td>
    </tr>
    <tr>
      <td>Such  <font color="blue">fluctuations</font>  have  often  been  unrelated to the operating  performance of these companies</td>
    </tr>
    <tr>
      <td>Nonetheless,  these  <font color="blue">broad market</font>  <font color="blue">fluctuations</font> may <font color="blue">negatively</font>  affect the <font color="blue">market price</font> of our common  stock</td>
    </tr>
    <tr>
      <td>Sales of  substantial  amounts of our <font color="blue">common stock</font> in the <font color="blue">open market</font>,  or  the  <font color="blue">availability</font> of such shares for sale,  could <font color="blue">adversely</font>  affect the price of  our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We had  44cmam289cmam161  shares of <font color="blue">common stock</font>  outstanding                                             24  <PAGE>    as of July 31, 2006</td>
    </tr>
    <tr>
      <td>The following  securities that may be <font color="blue">exercised into shares</font>  of our <font color="blue">common stock</font> were issued and <font color="blue">outstanding as</font> of July 31, 2006:          o     Options</td>
    </tr>
    <tr>
      <td>Stock options to purchase  3cmam830cmam350  shares of our common              stock at a <font color="blue">weighted average</font>  <font color="blue">exercise price</font> of  <font color="blue">approximately</font>  dlra3dtta10              per share</td>
    </tr>
    <tr>
      <td>Warrants to purchase 18cmam119cmam598 shares of our <font color="blue">common stock</font>              at a weighted  average  exercise  price of  <font color="blue">approximately</font>  dlra1dtta91 per              share</td>
    </tr>
    <tr>
      <td>The shares of our <font color="blue">common stock</font> that may be <font color="blue">issued under</font> the options and  warrants are currently  <font color="blue">registered with</font> the SEC or are eligible for sale without  any volume <font color="blue">limitations</font> pursuant to Rule 144(k) under the <font color="blue">Securities Act</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">incorporation</font>  <font color="blue">documents may delay</font> or prevent (i) the removal of our current  <font color="blue">management</font>  or  (ii) a  change  of  control  that  a  stockholder  may  consider  favorable</td>
    </tr>
    <tr>
      <td>We are currently  authorized to issue 1cmam000cmam000 shares of <font color="blue">preferred stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">Our Board of Directors </font>is authorized,  without any approval of the <font color="blue">stockholders</font>,  to issue the preferred  stock and  determine  the terms of the preferred  stock</td>
    </tr>
    <tr>
      <td>This  provision   allows  the  board  of  <font color="blue">directors</font>  to  affect  the  rights  of  <font color="blue">stockholders</font>, since the board of <font color="blue">directors</font> can make it more <font color="blue">difficult</font> for common  <font color="blue">stockholders</font> to <font color="blue">replace members</font> of the board</td>
    </tr>
    <tr>
      <td>Because the board of <font color="blue">directors</font> is  responsible for appointing the members of our <font color="blue">management</font>, these provisions could  in  turn  affect  any  attempt  to  replace  current  <font color="blue">management</font>  by the  common  <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>Furthermore, the existence of authorized shares of <font color="blue">preferred stock</font>  might have the effect of  <font color="blue">discouraging</font>  any  attempt  by a person,  through  the  <font color="blue">acquisition</font>  of a  substantial  number of shares of  common  stock,  to  acquire  control of our company</td>
    </tr>
    <tr>
      <td>Accordingly, the <font color="blue">accomplishment</font> of a <font color="blue">tender offer may</font> be  more <font color="blue">difficult</font></td>
    </tr>
    <tr>
      <td>This may be <font color="blue">beneficial</font> to <font color="blue">management</font> in a <font color="blue">hostile tender offer</font>,  but have an adverse  <font color="blue">impact on</font>  <font color="blue">stockholders</font>  who may want to <font color="blue">participate</font> in the  tender  offer or inhibit a  stockholderapstas  ability  to  receive  an  <font color="blue">acquisition</font>  premium for his or her shares</td>
    </tr>
    <tr>
      <td>The ability of our <font color="blue">stockholders</font> to <font color="blue">recover against</font> Armus Harrison &amp; Co, or AHC,  may be limited  because we have not been able to obtain the reissued  reports of  AHC <font color="blue">with respect</font> to the <font color="blue">financial statements</font> included in our Form 10-K, nor have  we been able to obtain AHCapstas consent to the use of such report herein</td>
    </tr>
    <tr>
      <td>Section 18 of the  Securities  <font color="blue">Exchange Act </font>of 1934 (the   &amp;quote Exchange  Act &amp;quote )  provides  that any  person  acquiring  or selling a security  in  reliance  upon  statements set forth in a Form 10-K may assert a claim <font color="blue">against every</font>  <font color="blue">accountant</font>  who has with its <font color="blue">consent been named as</font> having  prepared or certified any part of  the Form 10-K, or as having  prepared or certified any report or valuation  that  is used in  <font color="blue">connection</font>  with the Form 10-K, if that part of the Form 10-K at the  time it is <font color="blue">filed contains</font> a false or <font color="blue">misleading statement</font> of a material fact, or  omits a material  fact  required to be stated  therein or  <font color="blue">necessary</font> to make the  statements  therein not misleading (unless it is proved that at the time of such  <font color="blue">acquisition</font> such acquiring person knew of <font color="blue">such untruth</font> or omission)</td>
    </tr>
    <tr>
      <td>In June 1996, AHC dissolved and ceased all <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Therefore, we have  not  been  able to  obtain  the  reissued  reports  of AHC with  respect  to the  financial  statements  included  in the Form 10-K for the <font color="blue">fiscal year</font> ended July  31, 2006 nor have we been able to obtain AHCapstas consent to the use of such report  herein</td>
    </tr>
    <tr>
      <td>As a result, in the event any <font color="blue">persons seek</font> to assert a claim against AHC  under Section 18 of the <font color="blue">Exchange Act </font>for any <font color="blue">untrue statement</font> of a material fact  contained in these  financial  statements  or any  omissions to state a material  fact required to be stated  therein,  <font color="blue">such persons will</font> be barred</td>
    </tr>
    <tr>
      <td>Accordingly,  you may be unable to assert a claim against AHC under Section 18 of the Exchange  Act for any  purchases  of the  Companyapstas  Common  Stock made in  reliance  upon  statements  set forth in the Form 10-K for the <font color="blue">fiscal year</font> ended July 31,  2006</td>
    </tr>
    <tr>
      <td>In addition,  the ability of AHC to satisfy any claims properly  brought against  it may be limited as a practical matter due to AHCapstas <font color="blue">dissolution</font> in 1996</td>
    </tr>
  </tbody>
</table>